CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy.

Added 456 days ago (24.10.2020)
Authors: Willier S, Rothämel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T
PubMed id: 33094319
Read article